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an α arrestin protein that has attracted much attention as a multi 
functional regulator. Thioredoxin binding protein −2 expression is
downregulated in tumor cells and the level of thioredoxin binding
protein is correlated with clinical stage of cancer. Mice with muta 
tions or knockout of the thioredoxin binding protein −2 gene are
much more susceptible to carcinogenesis than wild type mice,
indicating a role for thioredoxin binding protein −2 in cancer
suppression. Studies have also revealed roles for thioredoxin bind 
ing protein −2 in metabolic control. Enhancement of thioredoxin
binding protein −2 expression causes impairment of insulin sensi 
tivity and glucose induced insulin secretion, and β cell apoptosis.
These changes are important characteristics of type 2 diabetes
mellitus. Thioredoxin binding protein −2 regulates transcription of
metabolic regulating genes. Thioredoxin binding protein −2 like
inducible membrane protein/ arrestin domain containing 3 regu 
lates endocytosis of receptors such as the β2 adrenergic receptor.
The α arrestin family possesses PPXY motifs and may function as
an adaptor/scaffold for NEDD family ubiquitin ligases. Elucidation
of the molecular mechanisms of α arrestin proteins would provide
a new pharmacological basis for developing approaches against
cancer and type 2 diabetes mellitus.
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Introduction We identified thioredoxin binding protein (TBP)-2 as a protein
that interacts with thioredoxin in the yeast-two hybrid
assay.(1) TBP-2 is identical to vitamin D3 upregulated protein
(VDUP)-1(2) and also is referred to as thioredoxin interacting
protein (Txnip).(3) Several groups reported interaction between
thioredoxin and this protein.(4,5) We and others showed that TBP-2
acts as a negative regulator of thioredoxin to inhibit its protein-
reducing activity.(1) Reports also show a reciprocal repression
pattern between TBP-2 and thioredoxin.(1,6,7) Although redox-
regulating activity of TBP-2 is one aspect of its function, TBP-2
seems to exert functions redox-independently. TBP-2 belongs to
the α-arrestin family and has arrestin domains with similarity to
those of β-arrestins.(8) Since β-arrestins are known to serve as
adaptor and scaffold proteins, TBP-2 may have similar functions.
TBP-2 is mainly located in the nucleus(9) and its expression is
induced by various stimuli. TBP-2 has a wide variety of biological
functions including regulation of cell death, growth, and differen-
tiation.
Although TBP-2 is reported to interact with JAB1,(10) histone
deacetylase (HDAC) 1, Fanconi anemia zinc-finger (FAZF),
promyelocytic leukemia zinc-finger (PLZF),(11) pVHL,(12) and
Dnajb5,(13) the physiological significance of each interaction has
not been fully clarified. In addition, the molecular and bio-
chemical mechanisms responsible for the pleiotropic functions of
TBP-2 have not been elucidated. Here, we review the mechanisms
of action and roles of TBP-2 in cancer suppression, immune and
inflammatory responses, and metabolism. In this review, animal
models in which the TBP-2/Txnip/VDUP1 gene is targeted are
termed as TBP-2−/− mice, Txnip knockout mice, Txnip-null mice,
and VDUP1−/− mice; the variations of each phenotype are dis-
played in Table 1.
TBP 2 and Thioredoxin
Several reports show that TBP-2 interacts with thioredoxin in
vitro and in vivo.(1,4,5) The finding that TBP-2 bound to wild-type
thioredoxin but not to a mutant with altered active site cysteines
suggests that TBP-2 attaches close to the active site of thioredoxin,
and that this interaction inhibits thioredoxin’s protein-reducing
activity. Indeed, overexpression of TBP-2 inhibited the reducing
activity of thioredoxin.(1,7,9) The C247 residue of TBP-2 is necessary
for the interaction between TBP-2 and thioredoxin, since TBP-2
C247S did not interact with thioredoxin in vitro.(14,15)
Interestingly, TBP-2 and thioredoxin sometimes display a
reciprocal expression pattern at the RNA level. In interleukin (IL)-
2-dependent CTLL-2 cells, deprivation of IL-2 caused upregula-
tion of TBP-2 expression, while thioredoxin expression was
downregulated (Ahsan et al., unpublished observation). TBP-2
expression was augmented and thioredoxin expression down-
regulated in HL60 cells treated with vitamin D3(1) or peroxisome
proliferator-activated receptor (PPAR) ligands(7) and in MCF-7
breast cancer cells treated with the HDAC inhibitor suberoylanilide
hydroxamic acid (SAHA).(6,16) The molecular mechanism under-
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lying this reciprocal gene expression pattern is currently unknown.
It may be that TBP-2 regulates transcription of the thioredoxin
gene. There are reports that upregulated TBP-2 expression causes
suppression of thioredoxin’s reducing activity resulting in oxida-
tive stress, which may lead to apoptosis. Based on the finding that
thioredoxin interacts with and regulates apoptosis signaling kinase
1 (ASK1),(17,18) it has been argued that TBP-2 binds to and oxidizes
thioredoxin or thioredoxin2, allowing for ASK1’s activation.(19–23)
The physiological significance of these findings should be verified
further.
The function of TBP-2, especially its metabolic regulating
function, however, is not explained by mere inhibition of thiore-
doxin, as discussed below. It should be noted that TBP-2-like
inducible membrane protein (TLIMP)/arrestin domain containing
3 (ARRDC3), another α-arrestin, does not bind to thioredoxin and
suppress its reducing activity. Among the TBP-2 family, only
TBP-2 interacts with thioredoxin,(7) a result confirmed by another
group.(14) These results suggest that α-arrestin proteins have
distinct roles other than suppression of thioredoxin.
TBP 2 Gene Expression
Expression level of TBP-2 is influenced by a variety of condi-
tions, suggesting roles in several biological processes. Currently
known stimuli and pathways are summarized in Fig. 1. Expression
of TBP-2 was upregulated in HL-60 cells stimulated with 1α,25-
dihydroxyvitamin D3,(1,2) and was augmented by glucose, ade-
nosine-containing molecules,(24) the HDAC inhibitor SAHA,(6) 5-
fluorouracil,(25) deprivation of serum or IL-2 in cell culture,(26,27)
carcinogens,(28) ceramide, etoposide,(20,29) hydrogen peroxide (H2O2),
heat shock,(5,29) transforming growth factor (TGF)-β,(11) ultraviolet
light,(30) glucocorticoid (GC),(31,32) allose treatment(33) and lipo-
polysaccharide (LPS).(34) An element containing two CCAAT
motifs in the gene regulatory region is required for a response to
vitamin D3(35) and NF-YA plays a role in vitamin D3-induced
activation of the TBP-2 gene (Masutani et al., unpublished obser-
vation). Upregulation of TBP-2 gene expression by SAHA is also
reported mediated by the CCAAT element and NF-YA.(6)
TBP-2 expression induced by glucose is mediated by carbo-
hydrate-response elements (ChoREs)(36,37) and the associated
transcription factors Max-like protein X (MLX) and Mondo
(MondoA or ChoRE-binding protein [ChREBP; also known as
MondoB]).(38–40) Glutamine inhibits transcriptional activation of
TBP-2 by triggering recruitment of an HDAC-dependent core-
pressor to the amino terminus of MondoA.(39) TBP-2 and
ARRDC4 expression is upregulated under lactic acidosis.(41)
Glucose-stimulated TBP-2 expression is regulated by forkhead
box O1 transcription factor (FOXO1) and p38 mitogen-activated
protein kinase (MAPK).(42) Overexpression of Krüppel-like factor
6 (KLF6) increased expression and promoter activity of TBP-2,
which was inhibited by concurrent exposure to a PPAR-γ
agonist.(43) In contrast, insulin is a potent repressor of TBP-2 ex-
pression.(44) Inhibitors of mitochondrial oxidative phosphorylation
downregulated TBP-2 expression at the transcriptional level.(45)
Tandem CCAAT boxes and ChoRE motifs and associated NF-Y
and Mondo/MLX transcription factors are required for enhancing
TBP-2 promoter activity.(46) Glucose-induced upregulation of TBP-
2 expression was suppressed by an inhibitor of p38 MAPK.(47,48)
One interesting report indicates the involvement of microRNA in
transcriptional regulation of TBP-2.(49) TBP-2 gene expression
was enhanced by a PPAR-α ligand and PPAR-γ agonists but not by
a PPAR-β/δ ligand.(7) An analysis of TBP-2 showed the presence
of a functional PPAR-γ response element in the promoter.(50) TBP-
2 levels were elevated in skeletal muscle of patients with impaired
glucose tolerance (IGT) or type 2 diabetes mellitus (T2DM).(51) A
thorough understanding of the mechanism regulating expression
of TBP-2 in glucose metabolism seems very important for
developing approaches against T2DM (discussed below). A
bilberry anthocyanin-rich extract altered TBP-2 expression in the
aorta of apo E-deficient mice.(52)  Trans-resveratrol suppressed
upregulation of TBP-2 expression occurring during liver ischemia–
reperfusion.(53) These natural products may be beneficial for
controlling levels of TBP-2.
Expression of TBP-2 has been analyzed in various stages of
the cellular differentiation process. TBP-2 expression was upregu-
lated in mesenchymal stem cells by glucose.(54) Blockade of the
N-methyl-D-aspartate (NMDA) receptor increased TBP-2 levels
in vivo and in vitro.(55) TBP-2 mRNA expression was augmented
Fig. 1. Transcriptional regulation of TBP 2. Gene expression of TBP 2 is enhanced by a wide variety of stimuli. For each stimulus, the specific
binding sequence and transcription factor are indicated. HSE, heat shock element;(29) PPRE, peroxisome proliferator activated receptor (PPAR)
response element;(50) AP 1, activator protein 1; GKLF, gut enriched Krüppel like factor; MZF1, myeloid zinc finger 1, putative FOXO1a binding site;(66)
and ChoRE: carbohydrate response element.(36,38) HSF1: heat shock factor 1; RXRα, retinoid X receptor α; KLF6, Krüppel like factor 6;(43) NF YA,
nuclear transcription factor Y subunit α; ChREBP, carbohydrate response element binding protein; Mlx, Max like protein X. J. Clin. Biochem. Nutr. | January 2012 | vol. 50 | no. 1 | 25
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in cerebellar granule neurons following their withdrawal from a
high-potassium medium.(56) Expression of TBP-2 decreased during
hematopoietic stem cell activation. A study on VDUP1−/− mice
suggests that TBP-2 may be essential for hematopoietic stem
cell quiescence.(57) TBP-2 expression is significantly induced in
fetal lung, suggesting that TBP-2 play some role in proliferation
and differentiation during pulmonary development.(58) The cis-
regulatory element of dvdup1, the drosophila TBP-2 homologue
gene, contains consensus binding sites for the glial fate gene
reversed polarity (repo)(59) and hedgehog-dependent transcription
factor,(60) suggesting that TBP-2 may be linked to neuronal growth
and development.
Several stimuli and conditions can cause suppression of TBP-2
expression. Expression of TBP-2 decreased in the presence of
soluble receptor activator of NF-κB ligand (sRANKL) and
overexpression of TBP-2 inhibited osteoclastogenesis.(61) Platelet-
derived growth factor (PDGF) and H2O2 treatment suppressed
TBP-2 expression in human aortic smooth muscle cells.(62)
Calcium channel blockers suppressed cardiac expression of TBP-2,
which may enhance cardiomyocyte survival.(63) Exenatide reduced
expression of TBP-2 and protected INS-1 β-cells against apop-
tosis.(64) Expression of TBP-2 in rat cardiomyocytes was rapidly
suppressed by biomechanical strain or H2O2.(65) One interesting
study found that TBP-2 expression was downregulated in human
compared with chimpanzees and TBP-2 may be a direct target of
FOXO1a.(66) TBP-2 expression was markedly suppressed by LPS
and interferon (IFN)-γ in macrophages, an effect that was partially
inhibited by an inducible nitric oxide synthase (iNOS) inhibitor.(67)
Trans-synaptic activation of synaptic NMDA receptors (NMDARs)
suppressed TBP-2 transcription by causing dissociation of FOXO
from the TBP-2 promoter via a phosphoinositide 3-kinase (PI3K)-
Akt pathway.(55) Knockdown of HDAC10 significantly increased
TBP-2 mRNA expression.(68) These results collectively imply
roles of TBP-2 for various cellular processes and disease condi-
tions (also discussed below). Studies are required to analyze the
mechanism behind suppression of TBP-2 gene expression (also
discussed below).
TBP 2 in Cancer Suppression
TBP-2 has growth-suppressive activity(1,9,11,26,69) and its aug-
mented expression is associated with apoptosis.(6,23,36,64,70–73)
Fibroblasts from VDUP1−/− mice proliferated more rapidly than
wild-type cells with reduced expression of p27 (kip1).(10) TBP-2 is
also a target for mediating GC-induced apoptosis.(31,32)
Many reports have shown downregulation of TBP-2 expression
in tumor cells and correlation of TBP-2 levels with clinical stages
of cancer. For instance, TBP-2 mRNA expression is down-
regulated in colorectal cancer.(74) TBP-2 expression was decreased
in colorectal and gastric cancer, and significantly lower in stage III
and IV tumors than stage II tumors.(75) The expression was also
decreased in primary breast and colon tumors,(6,75) human breast,
lung, and stomach cancers,(11) and 7,12-dimethylbenz(α)anthracene
(DBMA)-induced rat mammary adenocarcinomas.(76) Patients with
diffuse large B cell lymphomas who had the worst prognosis had
decreased levels of TBP-2.(77)
TBP-2 expression was abrogated in human T cell leukemia
virus type 1 (HTLV-I)-infected IL-2–independent T cells but
maintained in HTLV-I–infected IL-2–dependent T cells as well as
in HTLV-I–negative T cells.(26) Epigenetic silencing of the TBP-2
gene results in loss of responsiveness to IL-2.(27) Knockdown of
TBP-2 at an IL-2–dependent stage attenuated GC-induced cell
death, suggesting that TBP-2 mediates GC-induced cell death.(32)
In ferric nitrilotriacetate-induced carcinogenesis in rat kidney,
TBP-2 is silenced by epigenetic mechanisms during tumori-
genesis.(28) A recent report found that recruitment of HDAC1 to
the TBP-2 promoter was mediated by a complex consisting of the
RET finger protein and NF-Y. A high level of RET finger protein
was correlated with downregulation of TBP-2 expression in human
colon cancers and associated with poor clinical outcome.(78)
TBP-2 was expressed more markedly in nonmetastatic mela-
nomas than in parental metastatic cells.(79) Metastasis-free intervals
in 788 cases of breast cancer revealed that TBP-2 expression was
associated with a better prognosis.(80) TBP-2 expression was
downregulated significantly in malignant vs benign pheochro-
mocytoma.(81) These results suggest that TBP-2 is associated with
protection against metastasis.
The HcB-19 mouse strain, which has a spontaneous mutation in
the TBP-2 gene, was found associated with increased incidence of
hepatocellular carcinoma.(82) VDUP1−/− mice showed impaired NK
cell development and reduced tumor rejection.(83) TBP-2 expres-
sion is suppressed during human hepatic carcinogenesis, and
mice lacking TBP-2 (VDUP1−/−) were much more susceptible to
diethylnitrosamine-induced hepatocarcinogenesis than wild-type
mice.(84) These results suggest that a decrease of TBP-2 is
associated with tumorigenesis. Considering the retarded onset of
cancer in mice with disrupted expression of the TBP-2 gene, the
cancer-suppressive effect of TBP-2 seems attributable to the
progression phase of cancer development but not the initiation
phase. Although a regulatory role for TBP-2 in the tumor necrosis
factor (TNF)-α–NF-κB pathway is suggested during tumori-
genesis,(84) the underlying molecular mechanism of cancer sup-
pression by TBP-2 remains unclear.
TBP 2 in the Fasting Response
The clinical relevance of TBP-2 was first indicated by a sur-
prising report in 2002, demonstrating that TBP-2 is responsible for
the familial combined hyperlipidemia (FCHL) in HcB-19 mice,
which have a nonsense mutation in the TBP-2 gene and lack TBP-
2 expression.(3) Although mutation of TBP-2 was not detected in
human families with hyperlipidemia,(85–87) the finding was an
important indication that TBP-2 plays a role in metabolic control.
TBP-2−/− mice prepared by Oka et al.(88) are fertile and of normal
appearance. On fasting, however, they are predisposed to death
from hyperlipidemia, hypoglycemia, a bleeding tendency, and
hepato-renal insufficiency.(88) In mutant HcB-19 mice, plasma free
fatty acids levels are increased.(3,89) Fasted HcB-19 mice are also
hypoglycemic and hypertriacylglyceridemic and have higher
levels of ketone bodies.(90,91) These results show that HcB-19 mice
and TBP-2−/− mice exhibit very similar phenotypes and that TBP-
2 is a critical regulator of fasting responses.
Ablation of pancreatic β-cells with streptozotocin (STZ)
completely blocked the fasting-induced hypoglycemia and hyper-
triacylglyceridemia, suggesting that these abnormalities are due to
excess insulin secretion. Expression of insulin-inducible sterol-
responsive element-binding protein (SREBP)-1c and its target
genes was elevated.(90) Similar results were obtained in TBP-2−/−
mice. Gene chip analyses of the liver of TBP-2−/− mice showed that
considerable numbers of TBP-2-regulated genes are also fasting-
response genes. TBP-2 itself is one of the genes most upregulated
on fasting. A feature of TBP-2−/− mice is a change in gene expres-
sion of insulin and targets of SREBP such as fatty acid synthetase
and lipoprotein lipase in the fasted state. Intraperitoneal glucose
tolerance tests (IP-GTT) revealed increased insulin secretion in
TBP-2−/− mice. In intraperitoneal insulin tolerance tests (IP-ITT),
TBP-2−/− mice were demonstrated exposed to prolonged insulin
effects. These results suggest a role for TBP-2 in regulation of
insulin secretion and sensitivity, providing a possible link to
T2DM.(92)
Another feature of TBP-2−/− mice was upregulation of PPAR
target genes in the fed state.(92) Sheth et al.(91) also reported that
expression of PGC-1α was augmented in the liver of HcB-19
mice.(91) These results suggest that TBP-2 plays a role in PPAR-α
expression and signaling.
Txnip-null mice did not show hyperlipidemia,(93) unlike HcB-19doi: 10.3164/jcbn.11 36SR
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mutant mice,(3,89,90,91) TBP-2−/− mice(88) and total Txnip knockout
mice (Txnip-TKO).(94) The reason for the varied insulin levels
during fasting among the different mutants and constructs with a
disrupted TBP-2/Txnip/VDUP1 gene is unknown. It could be
caused by differences in experimental conditions for fasting and
susceptibility. Modifier gene effects resulting from strain differ-
ences among these models or contributions specific to the different
TBP-2 gene deletions may also play a role in the differences in β-
cell function.(93) The differences in metabolism among several
lines of mutant and knockout mice are summarized in Table 1.
Meanwhile, overexpression of TBP-2 in mice caused changes of
lipid metabolism, mirroring those in TBP-2−/− mice,(95) underlining
the significance of TBP-2 in metabolic control.
TBP 2 in T2DM
TBP-2 expression is elevated in skeletal muscle of patients with
impaired glucose tolerance or T2DM.(51) The frequency of a
3’UTR single nucleotide polymorphism in TBP-2 was investi-
gated in subjects with normal glucose tolerance, impaired glucose
tolerance, and T2DM. The frequency of the variation did not differ
among groups, but within the diabetic subjects, carriers of the T
variant had 1.6-fold higher triacylglyceride concentrations and a
higher diastolic blood pressure than homozygous carriers of the
common C-allele, whereas in nondiabetic subjects fasting glucose
was lower in carriers of the T-allele. These results imply the
involvement of TBP-2 in T2DM.(96)
Hyperglycemia and activation of receptor for advanced glyca-
tion end products induced expression of TBP-2 in cultured rat
retinal endothelial cells. TBP-2 overexpression in rat retinal
endothelial cells abolished H2K9 tri-methylation and increased
H3K9 acetylation, implying a role for TBP-2 in ocular inflam-
mation and endothelial dysfunction in patients with diabetic
retinopathy.(97) TBP-2 expression was rapidly induced in mesangial
cells in the kidney. Overexpression of TBP-2 resulted in induction
of type IV collagen alpha1 chain (COL4A1) mRNA expression
and accumulation of type IV collagen, indicating TBP-2 to be a
molecular mediator/marker for fibrosis in diabetic cases of
nephropathy.(98) As discussed above, studies have demonstrated
that TBP-2 expression is induced by glucose(36–40) and PPAR
ligands.(7,50) Results obtained with HcB-19 mutant mice(90) and
TBP-2−/− mice(92) indicate a regulatory role for TBP-2 in insulin
secretion and sensitivity. Crossing ob/ob mice with HcB-19 mice
provided protection against diabetes,(71) whereas disruption of
TBP-2 in ob/ob mice completely ameliorated hyperglycemia.(99)
These reports collectively demonstrate involvement of TBP-2 in
the pathophysiology of T2DM.
Regulation of Insulin Sensitivity by TBP 2
Knockdown of TBP-2 expression enhanced glucose uptake in
cultured adipocytes and primary human skeletal muscle myocytes,
whereas TBP-2 overexpression inhibited glucose uptake.(51)
Disruption of TBP-2 improves glucose tolerance and insulin
sensitivity.(92) HcB-19 mice crossed with ob/ob mice(71) and TBP-
2−/− mice crossed with ob/ob mice showed improved glucose
tolerance.(99) Augmented glucose transport was identified in
adipose tissue and skeletal muscle of Txnip-null mice.(100) Txnip-
TKO mice produced by Hui et al.(94) exhibited increased Akt
signaling and insulin sensitivity in skeletal muscle and hearts but
not liver and adipose tissue. Skeletal muscle glucose uptake was
increased in the Txnip-TKO mice. Muscle and heart-specific
Txnip knockout mice (Txnip-MKO) showed a similar metabolic
phenotype to the total knockout mice, but liver-specific Txnip
knock mice (Txnip-LKO) did not show metabolic changes.(94)
These results collectively demonstrate that TBP-2 deficiency
improves insulin sensitivity mainly in muscle.
Although altered production of adipocytokines accompanied
with obesity is implicated in insulin resistance and glucose
intolerance, TBP-2 deficiency improved insulin sensitivity without
any amelioration of obesity and adipocytokine levels.(99) TBP-2
deficiency in ob/ob mice restored Akt phosphorylation in the
skeletal muscle and heart but not liver. Several insulin signaling-
related genes such as Irs-1 (insulin receptor substrate-1; IRS-1)
were upregulated by the deficiency. IRS-1 protein levels were
downregulated in ob/ob mice, whereas IRS-1 levels and the
phosphorylation of Akt in response to insulin were restored by
TBP-2 deficiency in skeletal muscle. Thus TBP-2 regulates
expression of molecules involved in insulin signaling, which may
enhance insulin sensitivity in skeletal muscle.(99) The molecular
mechanism by which TBP-2 regulates expression of insulin
signaling-related genes remains to be elucidated.
Regulation of Insulin Secretion by TBP 2
A determinant of declining glucose tolerance is a progressive
decrease in glucose-stimulated insulin secretion (GSIS).(101) HcB-
19 and TBP-2−/− mice showed enhancement of insulin secretion in
vivo.(90,92) Decrease in β-cell mass after treatment with STZ was
greater in HcB-19 mice than control mice, suggesting that control
of β-cell mass may be one function of TBP-2.(102) However, no
significant change in islet mass between ob/ob·TBP-2−/− mice and
ob/ob mice or between TBP-2−/− and wild-type mice was observed.
Serum insulin levels after glucose loading in vivo were enhanced
in ob/ob·TBP-2−/− mice compared with ob/ob mice. In isolated
pancreatic islets, TBP-2 deficiency enhanced GSIS in wild-type
and ob/ob mice.(99) In addition, silencing of TBP-2 enhanced GSIS
in INS-1 cells, whereas TBP-2 overexpression suppressed
GSIS.(99) These results clearly revealed the regulatory role of
TBP-2 in GSIS.
Deficiency of TBP-2 enhanced mitochondrial ATP production
and GSIS in pancreatic β-cells.(99) Mitochondrial uncoupling
protein (UCP)-2 is a key regulator of ATP production and insulin
secretion in pancreatic β-cells and UCP-2 deficiency has been
shown to improve GSIS and glucose-induced ATP production in
ob/ob mice.(103) UCP-2 expression is upregulated with increases
Table 1. Phenotypes of mice with mutations or knockout of the TBP 2/Txnip/VDUP1 gene
1) HcB 19(3,82,90,91) Fasting induced hypoglycemia, hypertriacylglyceridemia, and hyperinsulinemia
2) TBP 2−/−(88,92) Fasting induced hypoglycemia, hypertriacylglyceridemia, and hyperinsulinemia
3) Txnip knockout mice (Txnip TKO)(94) Fasting induced hypoglycemia and hypertriacylglyceridemia; normal insulin levels
Liver specific Txnip knockout (Txnip LKO) No fasting induced changes
Muscle specific Txnip knockout (Txnip MKO) Fasting induced hypoglycemia and hypertriacylglyceridemia; normal insulin levels
4) Txnip null mice(100,118,130) Hypoglycemic and hypoinsulinemic; normal lipid levels
Liver specific Txnip null mice No change of glucose clearance
5) VDUP−/− mice(83,112) Improved glucose and insulin tolerance
6) β Cell–specific Txnip KO (Txnip bTKO)(71) Normal serum levels of triacylglycerides and ketones; reduced fasting blood glucose levels
7) BTBRlepob/obtxniphcb/hcb(71) Obese, protected against diabetes
8) C57BL6 lepob/obTBP 2−/−(99) Obese, protected against diabetes J. Clin. Biochem. Nutr. | January 2012 | vol. 50 | no. 1 | 27
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in the activity of PGC-1α.(104) TBP-2 enhanced expression and
transcriptional activity of UCP-2 by recruiting PGC-1α to the
UCP-2 promoter.(99)
While TBP-2 was reported to interact with various pro-
teins,(1,4,5,10,11) Mybbp1a was identified as a novel candidate binding
protein of TBP-2.(99) Mybbp1a is reported to inhibit PGC-1α
function and transcription of PGC-1α target genes through direct
protein–protein interaction.(105) As discussed below, TBP-2 may
interact with the WW domain of HECT domain-containing
ubiquitin ligases through its PPXY motifs. TBP-2 may negatively
regulate substrates such as Mybbp1a by protein degradation
through E3 ubiquitin ligases. The molecular mechanism by which
TBP-2 regulates metabolism should be investigated further.
Regulation of β Cell Apoptosis by TBP 2
TBP-2 is an important regulator of β-cell apoptosis.(106) TBP-2
is overexpressed in T2DM and induced by glucose to induce β-cell
apoptosis.(36,107) HcB-19 mouse islets were protected against
glucose-induced apoptosis.(108) Lack of TBP-2 inhibits the mito-
chondrial death pathway underlying β-cell glucotoxicity, but has
very few protective effects against endoplasmic reticulum (ER)
stress-mediated apoptosis.(72) HcB-19 mice crossed with ob/ob
mice against the BTBR background were protected from diabetes
and β-cell apoptosis at age 9 months, resulting in a 3-fold increase
in β-cell mass. β-Cell–specific Txnip knockout mice (Txnip-bKO)
also showed enhanced β-cell mass and revealed an approximately
50-fold reduction of β-cell apoptosis on STZ treatment.(71) In
C57BL/6J mice, TBP-2 deficiency also suppressed β-cell apoptosis
at age 36 weeks, although β-cell apoptosis did not occur signifi-
cantly in ob/ob and ob/ob·TBP-2−/− mice at age 10 weeks of age.(99)
These results clearly demonstrate that TBP-2 deficiency protects
against β-cell apoptosis in aged mice.
Collectively, TBP-2 deficiency ameliorates insulin sensitivity in
skeletal muscle and insulin secretion from pancreatic β-cells and
protects against β-cell apoptosis. Conversely, in obesity or under
conditions with augmented levels of free fatty acids and hyper-
glycemia the expression of TBP-2 is augmented, resulting in
impairments of insulin sensitivity and insulin secretion and
enhanced β-cell apoptosis. Augmented expression of TBP-2 might
also result in suppression of thioredoxin, which plays a protective
role against oxidative stress in β-cells(109,110) (Fig. 2). Thus TBP-2
seems an attractive target of drug development against T2DM.
Regulation of Immunity and Inflammation by TBP 2
TBP-2 is also involved in regulation of immunity and inflam-
mation. VDUP1−/− mice showed minimal changes in the develop-
ment of T and B cells but exhibited marked reduction in natural
killer (NK) cells as well as decreased NK activity. Expression of
CD122 was reduced, suggesting that TBP-2 is critical for develop-
ment and function of NK cells in vivo.(83) Dendritic cells (DCs)
derived from TBP-2−/− mice are defective in T cell activation. In a
mixed leukocyte reaction, and with LPS stimulation, IL-12 pro-
duction from Txnip−/− DCs was significantly lower than that from
wild-type DCs. The proliferation of T cells cultured with TBP-2−/−
DC was poorer than that with wild-type DCs.(111) The percentage
of hepatic NK T (NKT) cells decreased in TBP-2−/− mice but
increased in TBP-2 transgenic mice. TBP-2−/− mice were resistant
to concanavalin A-induced hepatitis.(95) TBP-2−/− mice injected
with LPS did not show higher serum levels of TNFα, IL-6, IL-10,
IFN-β, IFN-γ, monocyte chemoattractant protein (MCP) 1, and
macrophage inflammatory protein (MIP) 2 compared with wild-
type mice but exhibited fat accumulation in liver as well as
hypoglycemia and hyperinsulinemia similar to the phenotypes of
the fasted mice. Thus although TBP-2 may not directly regulate
LPS-induced inflammatory signaling, it influenced signaling in-
volved in metabolic control during LPS-induced endotoxemia.(34)
Very recently, there was a report that TBP-2 plays an important
role in inflammasome activation. The inflammasome is an emerging
concept of a mechanism of host defense. Macrophages have a
recognition system against pathogenic microbes and cellular stress
to activate caspase 1, leading to IL-1 secretion. TBP-2 interacts
with a nod-like receptor protein (NLRP) 3 inflammasome
Fig. 2. Aggravation of T2DM by TBP 2. In obesity, free fatty acids and hyperglycemia may augment expression of TBP 2. TBP 2 suppresses 1) insulin
sensitivity by decreasing Akt phosphorylation and expression of insulin signal regulating genes such as insulin receptor substrate 1 (IRS 1) gene in
muscle; and 2) glucose stimulated insulin secretion from pancreatic β cells by enhancing expression of uncoupling protein (UCP) 2; augments 3)
pancreatic β cell apoptosis; and also causes 4) suppression of thioredoxin. These changes may together lead to aggravation of diabetic phenotypes.doi: 10.3164/jcbn.11 36SR
©2012 JCBN
28
complex in macrophages leading to the NLRP3 inflammasome’s
activation in a reactive oxygen species (ROS)-sensitive manner.(112)
Subsequent study showed that TBP-2 is not involved in islet
amyloid polypeptide-induced activation of the NLRP3 inflam-
masome, analyzed in macrophage.(113) The significance of the role
of TBP-2 in regulation of inflammasome should be further verified.
Regulation of Vascular and Cardiac Function by TBP 2
The role of TBP-2 in vascular and cardiac function has been
investigated. Incubation of rat pulmonary artery smooth muscle
cells with the NO donor S-nitroso-glutathione suppressed TBP-2
expression.(114) TBP-2 has marked antiproliferative effects in
vascular smooth muscle cells.(62) TBP-2 protein expression is
upregulated in the lungs of 1-day-old newborn mice compared
with E19 embryos, showing an inverse correlation with expression
of vascular endothelial growth factor (VEGF). Overexpression of
TBP-2 inhibited hypoxia-inducible factor (HIF)-mediated reporter
activity, suggesting that TBP-2 is a potential regulator of HIF-
mediated gene transcription in the murine lung.(115) Exposure of
rabbit aortae or cultured endothelial cells to normal flow was
associated with decreased TBP-2 expression compared with
exposure to low flow. In aortae from HcB-19 mice, TNF-induced
vascular cell adhesion molecule (VCAM) 1 expression was
inhibited, indicating a role for TBP-2 in TNF signaling and
inflammation in endothelial cells in fluid shear stress.(19) A role for
TBP-2 in angiogenesis was also suggested.(116) The role and the
mechanism of involvement of TBP-2 in vasculature physiology
need further investigation.
Aortic constriction reduced TBP-2 expression. Cells over-
expressing TBP-2 develop less hypertrophy after aortic constric-
tion than control cells, suggesting that TBP-2 is a critical regulator
of biomechanical signaling.(117) Txnip-null mouse hearts had
attenuated cardiac hypertrophy and preserved left ventricular (LV)
contractile reserve through 4 weeks of pressure overload, whereas
TBP-2 deletion ultimately led to maladaptive LV remodeling at 8
weeks of pressure overload.(118) Therefore, the role of TBP-2 in
cardiac hypertrophy seems complex and requires further investi-
gation. Importantly, TBP-2 expression was significantly increased
in rat hearts following acute myocardial ischemia. Direct intra-
cardiac injection of sequence-specific DNA enzyme to down-
regulate TBP-2 mRNA at the time of acute cardiac infarction
reduced myocardial TBP-2 mRNA expression and resulted in a
prolonged reduction in cardiomyocyte apoptosis, accompanied by
a significant reduction in cardiac expression of pro-collagen type I
alpha2 mRNA as well as marked reduction of myocardial scar
formation. These results suggest a role for TBP-2 in the adverse
effects of ischemia.(22)
Involvement of TBP 2 in Other Diseases
TBP-2 deficiency enhances methionine–choline-deficient diet-
induced hepatic steatosis and inhibits nonalcoholic steatohepatitis
(NASH), suggesting that TBP-2 is involved in the pathogenesis of
NASH.(119) Recently, it was shown that in VDUP1−/− mice, liver
generation is accelerated after partial hepatectomy.(120) Another
report showed that TBP-2 expression was significantly lower in
ulcerative colitis colonic mucosa specimens than in normal
tissue.(74) TBP-2 protein level was increased in retinal ganglion
cells at 2 and 5 weeks after experimental glaucoma induction.(121)
Therefore, TBP-2 may be involved in the pathophysiology of
these diseases.
TBP 2 and α Arrestin Proteins and their Cellular Distribu 
tion
Phylogenic analysis revealed a large number of unrecognized
arrestins in eukaryotes termed α and β class arrestins.(8) β-Arrestin
is a scaffold/adaptor protein that interacts with various signaling
regulators such as MAPK and ASK1 and has a wide variety of
functions including the regulation of endocytosis and degradation
of surface receptors such as G coupled-protein receptors (GPCR).
The  α-arrestin family has arrestin domains and conserved
PPXY motifs and is found in all multicellular organisms except
plants. Since a subfamily (TBP-2, ARRDC2, ARRDC3, and
ARRDC4) has highly homologous protein sequence signature, it
seems reasonable to consider that TBP-2 belongs to a subfamily of
the α-arrestin family (Table 2). TBP-2 family members share 80%
amino acid similarity. ARRDC3 was originally reported as
TLIMP. We showed that TLIMP/ARRDC3 is a novel vitamin D3-
or PPAR-γ ligand-inducible membrane-associated protein and plays
a regulatory role in cell proliferation and PPAR-γ activation.(7)
Another homolog of TBP-2, DRH1, is identical to ARRDC4 and
reported downregulated in hepatocellular carcinoma cells.(122)
A clue to the functions of individual α-arrestin proteins is
provided by their cellular distribution. Although some reports
suggest that TBP-2 is expressed in mitochondria,(21,28,123) many
others indicate that it is expressed and functions primarily in the
nucleus.(9,12,21,92,99) Without stimulation in MCF-7 cells, TBP-2 was
hardly detectable in immunohistochemical analysis. On treatment
with the HDAC inhibitor SAHA, TBP-2 was detected mainly in
the nucleus.(9) TBP-2-EGFP displays scattered expression in about
30% of cells, indicating that TBP-2 functions mainly in the
nucleus. TBP-2 interacts with importin α, an important shuttle
between the cytosol and nucleus, in vitro and in vivo.
In contrast to the nuclear expression of TBP-2, expression of
TLIMP/ARRDC3 is on the inner side of the plasma membrane,
lysosome and endosome. These observations suggest that TLIMP/
ARRDC3 plays a role in the endocytotic process.(7) The membrane-
associated and endosomal expression was also confirmed by other
studies.(124,125) ARRDC4 occurs in the cytosol, whereas ARRDC2
is expressed in the nucleus (our unpublished observation).
ARRDC1 is located in the plasma membrane.(125)
TBP-2 family members have several similar characteristics. All
have growth suppressive activity. TBP-2 and TLIMP/ARRDC3
expression is induced by vitamin D3 and PPAR ligands.(7) On the
other hand, there may be differences among the TBP-2 family
members, including binding of thioredoxin as discussed above.(7,14)
Thus members of the TBP-2 family occur in each cellular
compartment and may have both common regulatory functions
and distinct functions. Further characterization of these proteins
is needed.
TBP 2 and NEDD Family Proteins
TBP-2 and other α-arrestin proteins have conserved PPXY
sequences that are known binding motifs for the WW domain(7,8,14,126)
(Fig. 3). Arrestin-related trafficking adaptors (ARTs) contain
PPXY motifs that interact with Rsp5/Nedd4-like ubiquitin ligase,
regulating the internalization of plasma membrane proteins
(cargos) and degradation in the lysosome in the yeast system.(127)
Art1 has considerable homology around the PPXY motif to
mammalian ARRDC proteins. It is worth noting that TLIMP/
ARRDC3 is also associated with the inner cellular membrane
and endosome/lysosome,(7) supporting the notion that ARRDC
Table 2. α Arrestin family proteins
Other name Localization
TBP 2 Txnip, VDUP1 Nucleus
ARRDC1 Membrane
ARRDC2 Nucleus
ARRDC3 TLIMP Inner membrane, endosome, lysosome
ARRDC4 DRH1 Cytosol
ARRDC5 J. Clin. Biochem. Nutr. | January 2012 | vol. 50 | no. 1 | 29
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proteins interact with NEDD family ubiquitin ligases to play a
regulatory role in endocytosis. Indeed, TLIMP/ARRDC3 directly
binds to a phosphorylated form of β4 integrin leading to its
internalization, ubiquitination, and ultimate degradation.(124)
Furthermore, TLIMP/ARRDC3 recruits NEDD4 to mediate
ubiquitination of the β2-adrenergic receptor(125) (Fig. 4). In human,
the NEDD family has nine members such as NEDD4, NEDD4L,
WWP1, WWP2, ITCH, SMURF1, SMURF2, HECW1, and
HECW2 (Table 3). One possibility is that as in the yeast system,
human α-arrestin proteins act as adaptors for ubiquitin ligases
(Fig. 5). On the other hand, human α-arrestin may be regulated
through degradation by the NEDD family. Various reports clearly
Fig. 3. α Arrestin family proteins. TBP 2/Txnip, ARRDC2, TLIMP/ARRDC3, and DRH1/ARRDC4 share high sequence homology. TBP 2 and ARRDC1, 2,
3, 4, and 5 all contain arrestin N and C domains. All but ARRDC5 possess conserved PPXY motifs.
Fig. 4. Regulation of G protein coupled receptors by TLMP/ARRDC3. TLIMP/ARRDC3 is reported to interact and co localize with the β2 adrenergic
receptor.(125) The β2 adrenergic receptor is a pharmacologically important G protein coupled receptor (GPCR) for regulation of dilation of bronchial
smooth muscle cells and therapy for bronchial asthma. TLIMP/ARRDC3 may regulate endocytosis, signaling, ubiquitination, and degradation of the
β2 adrenergic receptor.
Table 3. NEDD family proteins
Other name
NEDD4 NEDD4 1
NEDD4L NEDD4 2
WWP1 AIP5
WWP2 AIP2
ITCH AIP4
SMURF1
SMURF2
HECW1 NEDL1
HECW2 NEDL2doi: 10.3164/jcbn.11 36SR
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show that TBP-2 protein expression is rapidly turned over. It was
recently found that ITCH targets TBP-2 for ubiquitin-dependent
degradation.(73) Thus it is tempting to speculate that TBP-2 itself is
rapidly degraded by ubiquitin ligases and maintained at low levels,
and TBP-2 is stabilized by appropriate signal recognition and
translocated into the nucleus to interact with substrates for facili-
tating subsequent ubiquitination of the proteins. The interaction
between α-arrestin proteins and NEDD family ubiquitin ligases in
each cellular compartment should be investigated further.
Fig. 5. Hypothetical model of the interaction between α arrestin family proteins and NEDD family ubiquitin ligases. α Arrestin proteins containing
conserved PPXY motifs may interact with the WW domain of NEDD family ubiquitin ligases to regulate ubiquitination and degradation of substrate
proteins.
Fig. 6. Hypothetical model of reciprocal regulation between thioredoxin and TBP 2. TBP 2 is maintained at low levels and may be degraded by
NEDD family ubiquitin ligases such as ITCH. TBP 2 binds to importin α, moves to the nucleus, interacts with substrates, and may induce their
degradation by the NEDD family. TBP 2 also acts as a negative regulator of thioredoxin (TRX). Interaction between thioredoxin and TBP 2 might
regulate each other’s stability. TBP 2 might also transcriptionally regulate expression of thioredoxin. J. Clin. Biochem. Nutr. | January 2012 | vol. 50 | no. 1 | 31
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Regulation of Cellular Signals by Reciprocal Regulation
between Thioredoxin and TBP 2
Although TBP-2 seems to regulate metabolism mainly redox-
independently, TBP-2 could contribute to modulation of redox
status. In VDUP1−/− mice, the hepatomitogen-induced response
was associated with a considerable increase in the release of
TNF-α and subsequent enhancement of NF-κB activation on
TBP-2 deficiency.(84) Primary hepatocytes isolated from VDUP1−/−
mice displayed increased activation of ERK1/2 and Akt in
response to hepatocyte growth factor (HGF) and TGF-α.(120) These
results suggest that TBP-2 has a suppressive effect on growth
factor-induced signaling. Thioredoxin knockdown suppressed
epidermal growth factor (EGF)-induced ERK1/2 activation,
suggesting that thioredoxin plays a positive regulatory role in
ERK1/2 signaling.(128) It is tempting to speculate that TBP-2
deficiency results in augmentation of thioredoxin function, leading
to facilitation of growth factor signaling. It remains to be
elucidated how the stability of TBP-2 is regulated under various
forms of stress, during which the level of TBP-2 protein is
increased. Once stabilized, TBP-2 binds to importin α to transfer
to the nucleus and may interact with substrates, inducing them
into subsequent degradation by NEDD family protein ligases. A
schematic model of how TBP-2 regulates protein stability and
signals is displayed in Fig. 6. The possible mutual regulation
between TBP-2 and thioredoxin should be investigated further.
Perspectives
Accumulating evidence suggests that TBP-2 is a multifunc-
tional protein associated with various disease conditions such as
cancer, hyperlipidemia, T2DM, inflammatory diseases, cardiac
and vascular diseases, and NASH. The NEDD family is involved
in a variety of processes including transcription, receptor endo-
cytosis, membrane budding, and budding of viruses.(129) Further
elucidation of the molecular function of not only TBP-2 and
TLIMP/ARRDC3 but also other arrestin proteins will provide new
insights into clinical biochemistry and diseases such as cancer and
T2DM.
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ARRDC3 arrestin domain containing 3
ASK1 apoptosis signaling kinase 1
ChoRE carbohydrate response element
DC dendritic cell
FAZF Fanconi anemia zinc-finger
FOXO1 forkhead box O1 transcription factor
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HDAC histone deacetylase
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TBP-2 thioredoxin binding protein-2
T2DM type 2 diabetes mellitus
TGF transforming growth factor
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Txnip thioredoxin interacting protein
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